Article Text

Download PDFPDF
Acyclovir-induced thrombocytopaenia in a patient with SLE
  1. Irene Tsappa1,
  2. Constantinos Missouris1,2,
  3. Savvas Psarellis3
  1. 1 Medical School, University of Cyprus, Nicosia, Cyprus
  2. 2 Cardiology, Frimley Health NHS Trust, UK
  3. 3 Rheumatology, Nicosia General Hospital, Nicosia, Cyprus
  1. Correspondence to Dr Constantinos Missouris, dinos.missouris{at}


Acyclovir has been used in the treatment of herpes simplex and varicella zoster viral infections for over 30 years. The side effects of oral treatment at standard doses are rare and include headache, diarrhoea, dizziness and malaise. We report a patient with a new diagnosis of systemic lupus erythematosus (SLE) who developed thrombocytopaenia within days on a therapeutic dose with acyclovir. Prompt discontinuation of acyclovir and treatment with intravenous immunoglobulin resulted in reversal of the above potentially serious complication. Therefore a high index of suspicion should be exercised in patients with SLE who require treatment with acyclovir for herpes viral infections. In these patients regular platelet count measurement should be considered while on treatment with the above antiviral agent.

  • systemic lupus erythematosus
  • infections
  • unwanted effects/adverse reactions
  • haematology (drugs and medicines)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SP was the consultant responsible for the overall patient clinical care. IT together with SP developed the concept of acyclovir-induced thrombocytopaenia in a patient with SLE. CM performed the literature search and was instrumental together with the above collaborators in the preparation of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.